Polar Capital’s Array Biopharma Inc ARRY Stock Holding History

Polar Capital’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-400,000	Closed	-$5.7M	–	299
2018 Q4	$5.7M	Buy	400,000 +50,000	+14%	+$758K	0.06%	204
2018 Q3	$5.32M	Buy	+350,000	New	+$5.36M	0.05%	214
2018 Q1	–	Sell	-250,000	Closed	-$3.2M	–	285
2017 Q4	$3.2M	Hold	250,000	–	–	0.03%	222
2017 Q3	$3.08M	Buy	+250,000	New	+$2.32M	0.03%	213

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Polar Capital's ARRY Position: Q1 2019 in Review

Polar Capital sold out of Array Biopharma Inc (ARRY) in Q1 2019, closing a stake of 400,000 shares — an estimated $5.7M sold.

Polar Capital first reported a position in ARRY in Q3 2017 and held it in 4 quarters. The position peaked at $5.7M in Q4 2018. 268 funds tracked by Wall St. Rank hold ARRY as of Q1 2019.

Polar Capital reported no remaining Array Biopharma Inc position as of Q1 2019 after selling out during the quarter.
Polar Capital sold 400,000 Array Biopharma Inc shares in Q1 2019, an estimated $5.7M.
Polar Capital first reported a position in Array Biopharma Inc in Q3 2017 and held it in 4 quarters.
Polar Capital's Array Biopharma Inc position peaked at $5.7M in Q4 2018.
268 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2019.

Based on Polar Capital's 13F filing for Q1 2019, filed 15 May 2019.